AstraZeneca Allemansfond

Legal name: AstraZeneca Allemansfond
Equity Fund Registered in Sweden (Non-UCITS) Bid

About risk

Historical yields are not a guarantee of future returns. A fund can both increase and decrease in value and it is not guaranteed that you will recover the entire invested amount. Note that a fund with risk level 5-7, as stated in the fund's fact sheet (KID), can vary greatly in value due to the fund's composition and management methodology. The prospectus, fund rules and KID are available under each fund. Summary of investors' rights.

Fact sheet and documents Print page
Factsheet and Information Brochure
Factsheet 
Target Market
Costs and charges
Fund rules (136 kB)
Prospectus (1524 kB)
Periodic reports
Sustainability SFDR (1071 kB)
Annual review (PF) (3188 kB)
Semi-annual report (PF) (189 kB)
Marketing material
Brief fund information 
Summary SFDR (168 kB)
The fund is actively managed special fund (non-UCITS) and thereby the fund deviates from a UCITS fund by concentrating holdings to a smaller number of equities issued by companies in primarily Sweden. The fund invests a significant amount (maximum of 50% of assets) in AstraZeneca.

For this fund, the fund company's Enhanced exclusion level applies. For information about sectors that the fund excludes, see the Detailed information tab.

The fund is reported as an Article 8 fund pursuant to EU regulation 2019/2088 on sustainability-related disclosures in the financial services sector (SFDR).
Ulrika Orstadius

Fund manager

Ulrika Orstadius Experience in the fund industry 2011. Portfolio Manager since 1 November 2022.
Risk: 4/7
Risk  4/7
 
The risk indicator provides guidance on the risk level for this product relative to other financial products. It shows the likelihood that the product will decrease in value due to market performance. Risk level 1 represents a low risk and risk level 7 is a high risk.
Rating: 5
Total Rating™ 
31.03.2025
The rating shows which funds have historically posted the strongest performance in relation to risk. Ratings are denoted by a scale of one to five stars, with five as the highest rating. A fund must have a performance history of at least three years to receive a rating.
Read more about the fund's rating
EuapIndicator:1
SFDR
 
This fund promotes environmental and social characteristics through its investments but does not have sustainable investments as its objective. As a result, the fund takes into consideration the environment and climate, as well as human rights, employees’ rights and corruption.
The fund is reported as an Article 8 fund pursuant to EU regulation on sustainability-related disclosures in the financial services sector (SFDR).
  31.01.2025
Sustainability-
rating

The sustainability rating is developed by the fund information company Morningstar. The rating measures how well the fund's investee companies manage sustainability risks relative to other funds within the same global Morningstar category. If the fund has invested in government bonds issued by sovereign states, the respective country's sustainability risk is included in the calculation. The analyzed funds can receive a sustainability rating between 1 and 5 globes, with 5 as the highest rating.

The fund complies with the UN Principles for Responsible Investments.

Graph

In percent including distribution in SEK
Compare funds
AstraZeneca Allemansfond (SEK)

Note that benchmark returns, unlike fund returns, do not take distributions into account. As a result, fund returns are higher than they would otherwise be relative to benchmark.

Performance

Rate 17.04.2025 1 week 1 month 3 months 2025 1 year 5 years 10 years
3,597.09 SEK 1.54% -14.34% -10.62% -6.82% -6.69% 82.23% 175.80%

Portfolio 16.04.2025

Portfolio manager comments — Q1 2025
Fund performance was favorable during Q1 2025 and the fund rose 1.6% in SEK. Astra Zeneca, Volvo and SEB were the strongest contributors to fund returns. Astra Zeneca benefited when the investigation in China appeared to have less of an effect than expected. Volvo performed positively after a strong quarterly report and SEB has, in line with the rest of the bank sector, benefited in part from its domestic exposure.

Beijer Ref, Autoliv and Thule had the most negative impact during the period. Beijer Ref posted weak performance in line with the manufacturing sector, while Autoliv was affected by concerns about tariffs between the US and Mexico. Thule was weighed down by the market’s fears that the Q1 report would be below expectations.

The fund increased the holding in Astra Zeneca during the quarter as part of a rebalancing in the portfolio. Sandvik and Essity were also increased, due to our assessment of attractive valuations. At the same time, we decreased in Volvo due to greater uncertainty and chose to take profits in Handelsbanken during the quarter.

We continued to focus on investee companies that have sustainable business models and competitive offers with sustainable growth.

Portfolio distribution 31.03.2025

Geographic breakdown 31.03.2025

world_map